Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD - PACE-CME

Integrating antiPCSK therapy into primary and secondary prevention of CVD

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
AHA 2024
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
- Shawna Nesbitt, MD
Comprehensive management of individuals with CKM syndrome
Comprehensive management of individuals with CKM syndrome
MinuteCE®
Comprehensive management of individuals with CKM syndrome
1.00 program credit
- Muthiah Vaduganathan, MD
1.00 program credit
Effects of empaglifozin on kidney outcomes after acute MI
Effects of empaglifozin on kidney outcomes after acute MI
ESC Congress 2024
Effects of empaglifozin on kidney outcomes after acute MI
- Deepak Bhatt, MD